[go: up one dir, main page]

WO2009045412A3 - Methods of treatment using modified plasminogen activator inhibitor type-1 molecules - Google Patents

Methods of treatment using modified plasminogen activator inhibitor type-1 molecules Download PDF

Info

Publication number
WO2009045412A3
WO2009045412A3 PCT/US2008/011330 US2008011330W WO2009045412A3 WO 2009045412 A3 WO2009045412 A3 WO 2009045412A3 US 2008011330 W US2008011330 W US 2008011330W WO 2009045412 A3 WO2009045412 A3 WO 2009045412A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
plasminogen activator
activator inhibitor
molecules
inhibitor type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/011330
Other languages
French (fr)
Other versions
WO2009045412A2 (en
Inventor
Jerzy Jankun
Ewa Skrzypczak-Jankun
Steven H. Selman
Robert S. Greenfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Diagnostica Inc
University of Toledo
Original Assignee
American Diagnostica Inc
University of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Diagnostica Inc, University of Toledo filed Critical American Diagnostica Inc
Publication of WO2009045412A2 publication Critical patent/WO2009045412A2/en
Publication of WO2009045412A3 publication Critical patent/WO2009045412A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention generally relates to methods of treating bleeding diseases and disorders and to promote wound healing. The methods comprises administering a procoagulant, preferably factor VII a, and a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of the PAI-1 molecule. The invention also relates to methods of treating respiratory diseases using a modified PAI-1 molecule.
PCT/US2008/011330 2007-10-01 2008-10-01 Methods of treatment using modified plasminogen activator inhibitor type-1 molecules Ceased WO2009045412A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97665107P 2007-10-01 2007-10-01
US60/976,651 2007-10-01

Publications (2)

Publication Number Publication Date
WO2009045412A2 WO2009045412A2 (en) 2009-04-09
WO2009045412A3 true WO2009045412A3 (en) 2010-01-21

Family

ID=40526878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/011330 Ceased WO2009045412A2 (en) 2007-10-01 2008-10-01 Methods of treatment using modified plasminogen activator inhibitor type-1 molecules

Country Status (1)

Country Link
WO (1) WO2009045412A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150273A4 (en) * 2007-04-27 2010-11-17 Univ Toledo MODIFIED TYPE 1 PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHOD FOR ITS APPLICATION
CN106212126A (en) * 2016-08-11 2016-12-14 邱文娟 A kind of prevention and controls of Fructus Pruni pseudocerasi bleeding disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039028A1 (en) * 1996-04-12 1997-10-23 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
WO2003039580A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
WO2003080646A2 (en) * 2002-03-04 2003-10-02 Medical College Of Ohio Modified plasminogen activator inhibitor type-1 and methods based thereon
WO2004056384A2 (en) * 2002-12-20 2004-07-08 Novo Nordisk Health Care Ag Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039028A1 (en) * 1996-04-12 1997-10-23 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
WO2003039580A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
WO2003080646A2 (en) * 2002-03-04 2003-10-02 Medical College Of Ohio Modified plasminogen activator inhibitor type-1 and methods based thereon
WO2004056384A2 (en) * 2002-12-20 2004-07-08 Novo Nordisk Health Care Ag Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CATE JACQUELINE M ET AL: "Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent", CURRENT DRUG TARGETS, vol. 8, no. 9, September 2007 (2007-09-01), pages 971 - 981, XP008115249, ISSN: 1389-4501 *
DE TAEYE B ET AL: "The story of the serpin plasminogen activator inhibitor I: Is there any need for another mutant?", THROMBOSIS AND HAEMOSTASIS 200411 DE, vol. 92, no. 5, November 2004 (2004-11-01), pages 898 - 924, XP008115403, ISSN: 0340-6245 *
RENCKENS ROSEMARIJN ET AL: "Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia", BLOOD, vol. 109, no. 4, February 2007 (2007-02-01), pages 1593 - 1601, XP002557166, ISSN: 0006-4971 *
SISSON T H ET AL: "The plasminogen activation system in lung disease", CURRENT DRUG TARGETS 200709 NL, vol. 8, no. 9, September 2007 (2007-09-01), pages 1016 - 1029, XP008115250, ISSN: 1389-4501 *

Also Published As

Publication number Publication date
WO2009045412A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
UA98125C2 (en) Substituted dihydropyrazolon for the treatment of cardiovascular and haematological diseases
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA200970791A1 (en) N-ADAMANTYLBENZAMIDES AS INHIBITORS 11-β-HYDROXYSTEROID DEHYDROGENASE
WO2013061083A3 (en) Therapeutic agents and uses thereof
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2009002205A (en) Methods, compositions and apparatuses to treat wounds with pressures altered from atmospheric.
EP2484344A3 (en) Compositions and methods of using microspheres and non-ionic contrast agents
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2007100675A3 (en) Collagenase for treating cellulite
MX2010003095A (en) Antidotes for factor xa inhibitors and methods of using the same.
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
DE602005018763D1 (en) DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVA TO IMPROVE THE SLEEP QUALITY
WO2008103345A3 (en) Hemostatic compositions and therapeutic regimens
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2007058990A3 (en) Therapy using cytokine inhibitors
ATE476972T1 (en) USE OF VALPROIC ACID FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ACNE VULGARIS
MX2009011900A (en) Diabetic wound healing.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2009014564A3 (en) Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
GB2446341A (en) Method and system for transdermal drug delivery
WO2007100590A3 (en) Methods for treating cellulite
WO2009045412A3 (en) Methods of treatment using modified plasminogen activator inhibitor type-1 molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08836132

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08836132

Country of ref document: EP

Kind code of ref document: A2